Kinetek Pharmaceuticals

Kinetek Pharmaceuticals was a Canadian biotechnology company focused on the discovery and development of small molecule therapeutics targeting signal transduction pathways. The company's research centered on protein kinases and phosphatases, which play pivotal roles in regulating cell growth, differentiation, and metabolism. Kinetek's lead programs targeted integrin-linked kinase (ILK) for the treatment of various cancers and metabolic disorders like type 2 diabetes. Their proprietary proteomics-based platform allowed for the rapid identification and validation of novel drug targets. In 2004, the company was acquired by QLT Inc. in a deal valued at approximately $45 million, leading to the integration of its pipeline into QLT's portfolio.